The success of immune checkpoint blockade adds new therapeutic category to Cancers are the most heterogenous group of diseases affecting humans. Multiple compensating pathways work to promote disease progression. Various immunotherapies have shown anticancer promise, but the their targeted nature limits the scope of their action and applicability.
CAR T-cell therapy and bispecific antibodies are two approaches that have addressed the targeting of more than one epitope, the redirecting of T lymphocytes to kill tumor cells, and the improvement of efficacy in solid tumor types. For a closer look at the design, development, and success of CAR T-cell therapy and bispecific antibodies, a panel of experts come together to discuss their research and share insights into the potential these therapeutics hold in the fight against various tumor types.